ENZ - Enzo Biochem, Inc.
| Previous Close | 3.5800 |
| Open | 3.5800 |
| Bid | 3.6000 x 800 |
| Ask | 0.0000 x 800 |
| Day's Range | 3.5000 - 3.6950 |
| 52 Week Range | 2.3200 - 6.8900 |
| Volume | 185,317 |
| Avg. Volume | 194,606 |
| Market Cap | 171.486M |
| Beta (3Y Monthly) | 1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4910 |
| Earnings Date | Jun 9, 2017 - Jun 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- Thomson Reuters StreetEvents•21 days ago
Edited Transcript of ENZ earnings conference call or presentation 12-Mar-19 12:30pm GMT
Q2 2019 Enzo Biochem Inc Earnings Call
- Associated Press•last month
Enzo Biochem: Fiscal 2Q Earnings Snapshot
On a per-share basis, the New York-based company said it had a loss of 18 cents. The life sciences and biotechnology company posted revenue of $19.3 million in the period. In the final minutes of trading ...
- Business Wire•last month
Enzo Biochem Reports Second Fiscal Quarter and First Half 2019 Results and Reports Progress on Its Investments and Strategic Goals
Enzo Biochem, Inc. , an integrated diagnostics and therapeutics company, today reported results for the fiscal quarter and first half ended January 31, 2019 along with providing more detail on its investments in the development of novel diagnostic system and centralized clinical services.
- Business Wire•2 months ago
Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2019 Results Tuesday, March 12, 2019 at 8:30 AM E.T.
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 AM (E.T.) Tuesday March 26, 2019.
- Simply Wall St.•2 months ago
Why Enzo Biochem, Inc.’s (NYSE:ENZ) CEO Pay Matters To You
In 1976 Elazar Rabbani was appointed CEO of Enzo Biochem, Inc. (NYSE:ENZ). First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growth thatRead More...
- GlobeNewswire•3 months ago
Factors of Influence in 2019, Key Indicators and Opportunity within The Hain Celestial Group, Allegheny Technologies, NVR, Greif, CorMedix, and Enzo Biochem — New Research Emphasizes Economic Growth
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ENZ earnings conference call or presentation 11-Dec-18 1:30pm GMT
Q1 2019 Enzo Biochem Inc Earnings Call
- Simply Wall St.•4 months ago
How Many Insiders Bought Enzo Biochem, Inc. (NYSE:ENZ) Shares?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
- Associated Press•4 months ago
Enzo Biochem: Fiscal 1Q Earnings Snapshot
The New York-based company said it had a loss of 13 cents per share. The life sciences and biotechnology company posted revenue of $21.3 million in the period. In the final minutes of trading on Monday, ...
- Business Wire•4 months ago
Enzo Biochem Reports Fiscal 2019 First Quarter Results
Recent Reimbursement Cuts Emphasize Value of Enzo’s Strategy
- Business Wire•5 months ago
Enzo Biochem Schedules Teleconference to Discuss First Quarter 2019 Results Tuesday, December 11, 2018 at 8:30 AM E.T.
Enzo Biochem, Inc. , an integrated diagnostic and therapeutics company, will hold a conference call to discuss fiscal 2019 first quarter results Tuesday, December 11, 2018, at 8:30 AM E.T.
- Business Wire•5 months ago
Enzo Biochem Reports Publication of Study on Therapeutic Candidate SK1-I Detailing Promising Results in a Model of Treatment-Resistant Breast Cancer
Enzo Biochem, Inc. (ENZ), an integrated diagnostics and therapeutics company, today reported the publication of a study in the Journal of Lipid Research by researchers at a collaborating institution that shows SK1-I, the company’s proprietary Sphingosine Kinase 1 inhibitor drug candidate, was effective in reversing resistance to the breast cancer drug tamoxifen in a tamoxifen-resistant human breast cancer cell line. As pointed out in the publication, endocrine therapy, such as tamoxifen, is a first line treatment for estrogen receptor-positive breast cancer patients.
- Simply Wall St.•5 months ago
What Kind Of Shareholder Owns Most Enzo Biochem Inc (NYSE:ENZ) Stock?
The big shareholder groups in Enzo Biochem Inc (NYSE:ENZ) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own Read More...
- Benzinga•6 months ago
The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 16) Endo International PLC (NASDAQ: ENDP ) Krystal Biotech ...
- Thomson Reuters StreetEvents•6 months ago
Edited Transcript of ENZ earnings conference call or presentation 16-Oct-18 12:30pm GMT
Q4 2018 Enzo Biochem Inc Earnings Call
- Benzinga•6 months ago
The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 15) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...
- ACCESSWIRE•6 months ago
Enzo Biochem, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / October 16, 2018 / Enzo Biochem, Inc. (NYSE: ENZ ) will be discussing their earnings results in their 2018 FourthQuarter Earnings to be held on October16, 2018 at 8:30 AM Eastern ...
- Associated Press•6 months ago
Enzo Biochem: Fiscal 4Q Earnings Snapshot
NEW YORK (AP) _ Enzo Biochem Inc. (ENZ) on Monday reported a fiscal fourth-quarter loss of $5.8 million, after reporting a profit in the same period a year earlier. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.
- Business Wire•6 months ago
Enzo Biochem Reports Fourth Quarter and Fiscal 2018 Results
Molecular Assay Approvals from New York State Department of Health and Planned Acquisition of New Facility Highlight Progress Advancing Growth Strategy
- Business Wire•6 months ago
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter and Fiscal 2018 Results Tuesday, October 16, 2018 at 8:30 AM E.T.
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 AM (E.T.) Tuesday October 30, 2018.
- Investopedia•7 months ago
Top 5 Biotech Stocks for 2018
Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Given Celgene's solid long-term track record, the lackluster year-to-date performance may represent a buying opportunity.
- Business Wire•8 months ago
Enzo Biochem to Acquire New Facility for Manufacturing and Distribution to Advance Its Diagnostic and Therapeutic Growth Strategy
Enzo Biochem, Inc. (ENZ), an integrated diagnostic and therapeutics company, announced today that, as part of implementing its growth strategy, it has entered into an agreement to purchase a commercial facility with nearly 36,000 square feet in Farmingdale, NY. The building is adjacent to the Company’s current Long Island campus and enhances the infrastructure needed to produce and distribute Enzo’s expanding low cost, diagnostic platform products and related services. The Company’s platform development includes automation-compatible reagent systems and associated products for sample collection and processing through analysis.
